This research study tests a medicine called ianalumab given as a shot under the skin to help treat lupus nephritis (LN), a kidney disease caused by lupus. The medicine will be compared to a placebo, which is a treatment with no active medicine. People in the study will also receive standard care (SoC) treatment. Participants will receive ianalumab every 4 weeks or every 12 weeks.

To join the study, you must be 18 or older, weigh at least 35 kg, and have a confirmed diagnosis of lupus. You also need to have active LN, which will be confirmed by a kidney test called a biopsy. If you have a serious kidney problem or have used specific medicines recently, you may not be able to join.

• The study will last several months with regular doctor visits for treatments and check-ups.
• Participants may receive a new treatment or a placebo, along with their regular medication.
• There may be some risks, like side effects from the medicine or the placebo.

Discuss with your doctor if this study is right for you.